Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

LIFE

Atyr Pharma Inc

May 01 • 04:00PM ET

1.59

Dollar change +0.02
Percentage change 1.27	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC DFAT DFUS

Index	-	P/E	-	EPS (ttm)	-0.95	Insider Own	3.09%	Shs Outstand	67.75M	Perf Week	-0.62%
Market Cap	107.72M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	1.38%	Shs Float	65.66M	Perf Month	-13.59%
Income	-50.39M	PEG	-	EPS next Q	-0.25	Inst Own	60.59%	Short Float	0.58%	Perf Quarter	-0.31%
Sales	0.35M	P/S	307.78	EPS this Y	-5.59%	Inst Trans	0.61%	Short Ratio	0.68	Perf Half Y	27.20%
Book/sh	1.43	P/B	1.11	EPS next Y	5.29%	ROA	-46.26%	Short Interest	0.38M	Perf Year	-24.29%
Cash/sh	1.45	P/C	1.10	EPS next 5Y	13.00%	ROE	-62.16%	52W Range	1.08 - 2.70	Perf YTD	12.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	43.36%	ROI	-48.25%	52W High	-41.11%	Beta	1.27
Dividend TTM	-	Quick Ratio	6.27	Sales past 5Y	436.18%	Gross Margin	-676.49%	52W Low	47.21%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	6.27	EPS Y/Y TTM	40.37%	Oper. Margin	-15557.79%	RSI (14)	38.94	Volatility	3.68% 5.03%
Employees	59	Debt/Eq	0.17	Sales Y/Y TTM	-96.60%	Profit Margin	-14274.50%	Recom	1.00	Target Price	25.25
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	3.56%	Payout	-	Rel Volume	1.10	Prev Close	1.57
Sales Surprise	-100.00%	EPS Surprise	-5.04%	Sales Q/Q	-100.00%	Earnings	Mar 14 AMC	Avg Volume	565.18K	Price	1.59
SMA20	-5.68%	SMA50	-11.06%	SMA200	-1.52%	Trades		Volume	619,697	Change	1.27%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform	$22
Sep-21-21	Initiated	Piper Sandler	Overweight	$19
May-10-21	Initiated	Laidlaw	Buy	$18
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy	$13
Mar-04-20	Initiated	ROTH Capital	Buy	$15
Mar-02-20	Initiated	Oppenheimer	Outperform	$8
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight	$7
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	JP Morgan	Overweight	$44
Jun-01-15	Initiated	Citigroup	Buy	$32

Show Previous Ratings

Apr-01-24 08:00AM	aTyr Pharma to Participate in April Investor Conferences (GlobeNewswire)
Mar-26-24 02:19PM	3 Penny Stocks That Could Be Multibaggers in the Making: March Edition (InvestorPlace)
Mar-15-24 01:33PM	aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript (Insider Monkey) +22.84%
11:30AM	Q4 2023 aTyr Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
11:01AM	aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress (GuruFocus.com)
08:56PM	Loading…
Mar-14-24 08:56PM	LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023 (InvestorPlace)
04:16PM	Atyr Pharma: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update (GlobeNewswire)
Feb-28-24 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results (GlobeNewswire) -5.00%
Feb-21-24 08:00AM	aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT Clinical Trial Participants (GlobeNewswire)
Jan-29-24 08:00AM	aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity (GlobeNewswire)
Jan-18-24 08:00AM	aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor (GlobeNewswire)
Nov-13-23 08:00AM	aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023 (GlobeNewswire)
Nov-09-23 04:07PM	Atyr Pharma: Q3 Earnings Snapshot (Associated Press Finance) -5.74%
04:00PM	aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
Nov-01-23 08:00AM	aTyr Pharma to Present at November Investor Conferences (GlobeNewswire)
Oct-31-23 08:00AM	aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD (GlobeNewswire)
Sep-11-23 08:00AM	aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes (GlobeNewswire)
Aug-30-23 09:35AM	Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE) (Zacks)
Aug-24-23 08:00AM	aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 05:30PM	Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:29PM	Atyr Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
Jul-20-23 07:30AM	aTyr Pharma, Inc. (NASDAQ:LIFE) is a favorite amongst institutional investors who own 56% (Simply Wall St.)
Jun-28-23 07:00AM	7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023 (InvestorPlace)
Jun-22-23 08:00AM	European Commission Grants Orphan Drug Designation for aTyr Pharmas Efzofitimod for Treatment of Systemic Sclerosis (GlobeNewswire)
Jun-20-23 08:00AM	aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference (GlobeNewswire)
Jun-09-23 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-23 08:00AM	aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023) (GlobeNewswire)
May-25-23 08:00AM	aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
08:00AM	Loading…
May-22-23 08:00AM	aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference (GlobeNewswire)
07:33AM	Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data (Investing.com)
May-13-23 08:06AM	aTyr Pharma Independent Director Acquires 25% More Stock \ (Simply Wall St.)
May-11-23 04:00PM	aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-10-23 06:11AM	aTyr Pharma (NASDAQ:LIFE) investors are sitting on a loss of 89% if they invested five years ago (Simply Wall St.) +6.10%
May-09-23 05:15PM	Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Atyr Pharma: Q1 Earnings Snapshot (AP Finance)
04:00PM	aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
May-07-23 04:00AM	3 Stocks and Cryptos With the Highest Potential Returns (InvestorPlace)
May-05-23 02:24PM	7 Hot Growth Stocks Poised to Triple in 2023 (InvestorPlace)
Apr-17-23 08:00AM	aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting (GlobeNewswire)
Mar-30-23 08:00AM	aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases (GlobeNewswire)
Mar-28-23 10:45AM	2 Strong Buy Penny Stocks With Over 200% Upside on the Horizon (TipRanks) +9.64%
Mar-23-23 07:10AM	Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation (Simply Wall St.)
Mar-21-23 08:00AM	aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution (GlobeNewswire)
Mar-20-23 08:00AM	aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies (GlobeNewswire)
Mar-09-23 05:15PM	Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.18%
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update (GlobeNewswire)
Mar-08-23 08:00AM	aTyr Pharma to Present at March Investor Conferences (GlobeNewswire)
Mar-02-23 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results (GlobeNewswire)
Mar-01-23 08:00AM	aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application (GlobeNewswire)
Feb-17-23 12:00PM	Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-10-23 05:21AM	With 37% stake, aTyr Pharma, Inc. (NASDAQ:LIFE) seems to have captured institutional investors' interest (Simply Wall St.)
Feb-09-23 08:00AM	aTyr Pharma Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -7.56%
Feb-08-23 04:11PM	aTyr Pharma Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
Feb-06-23 08:00AM	aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd. (GlobeNewswire) +6.52%
Jan-31-23 08:00AM	aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference (GlobeNewswire)
Jan-19-23 08:00AM	aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis (GlobeNewswire)
Jan-18-23 08:00AM	European Commission Grants Orphan Drug Designation for aTyr Pharmas Efzofitimod for Treatment of Sarcoidosis (GlobeNewswire)
Dec-29-22 06:59PM	aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-15-22 08:00AM	aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment (GlobeNewswire)
Nov-18-22 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-22 05:15PM	Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:00PM	aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-09-22 08:00AM	aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST (GlobeNewswire)
Nov-03-22 08:02AM	aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-25-22 08:00AM	aTyr Pharma to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-11-22 08:00AM	aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets (GlobeNewswire)
Oct-04-22 08:00AM	aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium (GlobeNewswire) +6.64%
Sep-29-22 08:00AM	aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies (GlobeNewswire)
Sep-27-22 08:00AM	aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis (GlobeNewswire)
Sep-16-22 08:35AM	Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing (GlobeNewswire) -6.73%
Sep-13-22 08:00AM	aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) (GlobeNewswire)
Sep-12-22 08:35AM	Life Sciences Virtual Investor Conference Agenda Announced for September 15th (GlobeNewswire)
Sep-09-22 11:52AM	Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation (Simply Wall St.)
08:00AM	aTyr Pharma to Present at the Life Sciences Investor Forum on September 15th (GlobeNewswire)
Sep-06-22 08:00AM	aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022 (GlobeNewswire)
Sep-01-22 08:00AM	aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022 (GlobeNewswire)
Aug-15-22 04:00PM	aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
Aug-12-22 04:05PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-22 08:03AM	aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis (GlobeNewswire)
Aug-04-22 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-24-22 02:22PM	Bullish aTyr Pharma, Inc. (NASDAQ:LIFE) insiders filled their treasuries with US$2.1m worth of stock over last year (Simply Wall St.)
Jun-14-22 08:00AM	aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment (GlobeNewswire)
Jun-13-22 08:00AM	aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference (GlobeNewswire) -6.03%
Jun-01-22 08:00AM	aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-17-22 08:00AM	aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference (GlobeNewswire)
May-16-22 08:00AM	aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis (GlobeNewswire)
May-13-22 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-22 02:00PM	Is aTyr Pharma, Inc. (NASDAQ:LIFE) Popular Amongst Institutions? (Simply Wall St.)
08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences in May (GlobeNewswire)
May-09-22 05:15PM	Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.07%
04:00PM	aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
02:40AM	Love Hemp Group PLC Announces Update Regarding Trading Suspension (ACCESSWIRE)
May-02-22 08:00AM	aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results (GlobeNewswire)
Apr-14-22 12:14PM	aTyr Pharma (LIFE) Up on Orphan Drug Status for Efzofitimod (Zacks)
Apr-13-22 08:00AM	aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis (GlobeNewswire) +7.38%
Apr-11-22 08:00AM	aTyr Pharma Presents Preclinical Research Characterizing Effects of ATYR2810 in Highly Aggressive Tumor Subtypes at the 2022 AACR Annual Meeting (GlobeNewswire)
Apr-06-22 09:55AM	Does Atyr Pharma (LIFE) Have the Potential to Rally 236% as Wall Street Analysts Expect? (Zacks)

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Broadfoot Jill Marie	Chief Financial Officer	Feb 06 '24	Sale	1.69	1,590	2,687	20,821	Feb 06 08:18 PM
Shukla Sanjay	President and CEO	Dec 12 '23	Buy	1.18	12,000	14,136	106,173	Dec 12 06:50 PM
Shukla Sanjay	President and CEO	Dec 11 '23	Buy	1.17	3,000	3,510	94,173	Dec 12 06:50 PM
Shukla Sanjay	President and CEO	Nov 13 '23	Buy	1.11	13,578	15,085	91,173	Nov 13 04:11 PM
Shukla Sanjay	President and CEO	Nov 10 '23	Buy	1.14	1,422	1,618	77,595	Nov 13 04:11 PM
Shukla Sanjay	President and CEO	Jul 28 '23	Buy	2.01	15,000	30,224	76,173	Aug 01 04:07 PM
SCHIMMEL PAUL	Director	May 10 '23	Buy	2.25	200,000	450,000	313,023	May 11 09:00 AM

Open in Screener

TVTX

Travere Therapeutics Inc

May 01 • 04:00PM ET

6.00

Dollar change +0.47
Percentage change 8.50	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

TVTX Travere Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO IBB LABU VTWO VHT SCHA ITOT

Index	RUT	P/E	-	EPS (ttm)	-4.56	Insider Own	1.41%	Shs Outstand	75.37M	Perf Week	10.09%
Market Cap	456.60M	Forward P/E	-	EPS next Y	-1.85	Insider Trans	-5.26%	Shs Float	75.03M	Perf Month	-14.77%
Income	-337.40M	PEG	-	EPS next Q	-0.94	Inst Own	113.78%	Short Float	15.73%	Perf Quarter	-32.81%
Sales	198.84M	P/S	2.30	EPS this Y	-94.39%	Inst Trans	0.10%	Short Ratio	9.73	Perf Half Y	-11.24%
Book/sh	2.66	P/B	2.25	EPS next Y	36.70%	ROA	-47.87%	Short Interest	11.80M	Perf Year	-73.46%
Cash/sh	7.45	P/C	0.81	EPS next 5Y	-	ROE	-287.12%	52W Range	5.12 - 22.75	Perf YTD	-33.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.34%	ROI	-56.17%	52W High	-73.63%	Beta	0.69
Dividend TTM	-	Quick Ratio	3.41	Sales past 5Y	3.07%	Gross Margin	69.95%	52W Low	17.19%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	3.47	EPS Y/Y TTM	-4.33%	Oper. Margin	-171.72%	RSI (14)	43.15	Volatility	7.86% 5.96%
Employees	380	Debt/Eq	2.02	Sales Y/Y TTM	-6.21%	Profit Margin	-169.68%	Recom	1.69	Target Price	15.00
Option/Short	Yes / Yes	LT Debt/Eq	1.99	EPS Q/Q	-15.12%	Payout	-	Rel Volume	1.55	Prev Close	5.53
Sales Surprise	8.08%	EPS Surprise	-1.94%	Sales Q/Q	-19.35%	Earnings	May 06 AMC	Avg Volume	1.21M	Price	6.00
SMA20	-2.58%	SMA50	-16.48%	SMA200	-35.53%	Trades		Volume	1,882,671	Change	8.50%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22
Dec-05-22	Initiated	Wells Fargo	Overweight	$28
Sep-21-22	Initiated	Bryan Garnier	Sell	$17
Jul-14-22	Resumed	Canaccord Genuity	Buy	$49 → $42
Mar-31-22	Initiated	Piper Sandler	Overweight	$42
Feb-28-22	Initiated	H.C. Wainwright	Buy	$45
May-26-21	Downgrade	Wedbush	Outperform → Neutral	$19

Show Previous Ratings

Apr-29-24 04:30PM	Travere Therapeutics to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 07:05AM	Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy (GlobeNewswire) -5.05%
03:00AM	CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI (sparsentan) for the treatment of IgA Nephropathy (PR Newswire)
Apr-04-24 04:30PM	Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International (GlobeNewswire)
Apr-03-24 04:30PM	Travere Therapeutics to Present Abstracts on FILSPARI (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association (GlobeNewswire)
05:00PM	Loading…
Mar-13-24 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.16%
Mar-11-24 07:05AM	Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN) (GlobeNewswire) -7.74%
Feb-26-24 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-23-24 07:05AM	Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy (GlobeNewswire)
02:00AM	CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy (PR Newswire)
Feb-16-24 09:52AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript (Insider Monkey) -6.18%
Feb-15-24 04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +5.94%
Feb-08-24 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-01-24 04:30PM	Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-25-24 04:05PM	Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations (GlobeNewswire)
07:00AM	Loading…
Jan-08-24 07:00AM	Travere Therapeutics Provides Corporate Update and 2024 Outlook (GlobeNewswire) +13.66%
Jan-02-24 04:30PM	Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.34%
Dec-14-23 07:30AM	Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU) (GlobeNewswire)
Dec-04-23 04:05PM	Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS (GlobeNewswire)
Nov-21-23 04:30PM	Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-09-23 06:26PM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2023 Earnings Call Transcript (Insider Monkey) -14.06%
Nov-07-23 04:01PM	Travere Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire) +8.13%
Nov-03-23 10:46AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire) +5.93%
Oct-24-23 04:30PM	Travere Therapeutics to Report Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-13-23 04:30PM	Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023 (GlobeNewswire)
Oct-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-23 04:30PM	Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023) (GlobeNewswire) +5.96%
Sep-22-23 09:38AM	Wayfair upgraded, Deere downgraded: Wall Street's top analyst calls (The Fly)
Sep-21-23 07:30AM	Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan (GlobeNewswire) -40.68%
Sep-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:30AM	Loading…
Sep-05-23 08:30AM	Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals (GlobeNewswire)
08:30AM	Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Aug-31-23 04:30PM	Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference (GlobeNewswire) +8.26%
Aug-24-23 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023 (GlobeNewswire)
Aug-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-23 06:03AM	News Flash: Analysts Just Made A Notable Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Forecasts (Simply Wall St.)
Aug-03-23 04:01PM	Travere Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-26-23 12:28PM	J.P. Morgan Recommends These 2 Strong Buy Stocks Including One With 90% Upside Potential (TipRanks)
Jul-20-23 04:30PM	Travere Therapeutics to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-17-23 08:00AM	Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals (GlobeNewswire)
08:00AM	Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Jul-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-08-23 04:30PM	Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023 (GlobeNewswire) -7.39%
Jun-01-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-31-23 07:00AM	Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria (GlobeNewswire) +9.02%
May-11-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-04-23 04:01PM	Travere Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-01-23 04:05PM	Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis (GlobeNewswire)
Apr-26-23 04:30PM	Travere Therapeutics to Report First Quarter 2023 Financial Results (GlobeNewswire)
Apr-13-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-23 04:30AM	Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 (GlobeNewswire)
Mar-28-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Mar-23-23 04:30PM	Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023 (GlobeNewswire)
Mar-14-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:30PM	Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023 (GlobeNewswire)
Mar-03-23 04:05PM	Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Feb-28-23 10:36PM	Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Feb-27-23 04:01PM	Travere Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-25-23 07:35AM	Travere Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
Feb-23-23 04:01PM	Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-17-23 06:30PM	Ligands Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (Business Wire) -12.22%
04:04PM	Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (GlobeNewswire)
04:04PM	Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy (GlobeNewswire)
Feb-16-23 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-13-23 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-08-23 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-12-23 07:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-09-23 07:00AM	Travere Therapeutics Provides Corporate Update and 2023 Outlook (GlobeNewswire)
Jan-03-23 04:30PM	Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-16-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-15-22 08:00AM	Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease (GlobeNewswire)
Nov-09-22 04:30PM	Travere Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-27-22 04:01PM	Travere Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-26-22 04:30PM	Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022 (GlobeNewswire)
Oct-20-22 04:30PM	Travere Therapeutics to Report Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-13-22 04:05PM	Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy (GlobeNewswire)
Oct-11-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-25-22 04:30PM	Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium (GlobeNewswire)
Aug-22-22 07:00AM	Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy (GlobeNewswire)
Aug-11-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-04-22 07:00AM	Travere Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +7.46%
Aug-03-22 04:05PM	Travere Therapeutics Provides Regulatory Updates on its Development Programs (GlobeNewswire)
Jul-28-22 04:30PM	Travere Therapeutics to Report Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-12-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-20-22 09:18AM	Health Check: How Prudently Does Travere Therapeutics (NASDAQ:TVTX) Use Debt? (Simply Wall St.)
Jun-14-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-22 04:30PM	Travere Therapeutics to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-17-22 04:30PM	Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress (GlobeNewswire) +9.09%
May-16-22 04:09PM	Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug (Investor's Business Daily) +6.13%
07:00AM	Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy (GlobeNewswire)
May-11-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-05-22 04:01PM	Travere Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) -5.09%
May-03-22 04:30PM	Travere Therapeutics to Present at the BofA Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-28-22 04:30PM	Travere Therapeutics to Report First Quarter 2022 Financial Results (GlobeNewswire)
Apr-20-22 04:30PM	Travere Therapeutics Announces Plan for Chief Financial Officer Transition (GlobeNewswire)
Apr-12-22 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-11-22 08:08AM	Travere Therapeutics' (NASDAQ:TVTX) growing losses don't faze investors as the stock ascends 5.1% this past week (Simply Wall St.)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 11 '24	Sale	6.74	54	364	70,849	Apr 12 04:05 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 01 '24	Sale	8.70	19,122	166,435	350,600	Feb 02 04:06 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Feb 01 '24	Sale	8.71	4,764	41,495	76,270	Feb 02 04:05 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Feb 01 '24	Sale	8.71	4,764	41,495	80,720	Feb 02 04:05 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 01 '24	Sale	8.53	4,195	35,789	99,503	Feb 02 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 01 '24	Sale	8.53	3,818	32,573	70,903	Feb 02 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 01 '24	Sale	8.53	2,820	24,058	52,017	Feb 02 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 01 '24	Sale	8.53	2,174	18,547	58,074	Feb 02 04:05 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '24	Sale	8.96	7,873	70,542	234,722	Jan 25 04:10 PM
ROTE WILLIAM E.	SENIOR VICE PRESIDENT, R&D	Jan 23 '24	Sale	8.96	2,062	18,476	60,484	Jan 25 04:10 PM
REED ELIZABETH E	SVP, GC & CORPORATE SECRETARY	Jan 23 '24	Sale	8.96	2,062	18,476	56,034	Jan 25 04:10 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Jan 23 '24	Sale	9.07	1,559	14,138	78,698	Jan 25 04:10 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Jan 23 '24	Sale	9.07	910	8,252	41,337	Jan 25 04:10 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Jan 23 '24	Sale	9.07	853	7,735	49,721	Jan 25 04:10 PM
Inrig Jula	Chief Medical Officer	Jan 04 '24	Sale	9.17	440	4,035	35,248	Jan 05 04:11 PM
Inrig Jula	Chief Medical Officer	Jan 03 '24	Sale	9.48	2,069	19,613	35,688	Jan 05 04:11 PM
Heerma Peter	Chief Commercial Officer	Oct 03 '23	Sale	8.25	3,091	25,504	80,257	Oct 04 04:05 PM
Dube Eric M	Chief Executive Officer	Sep 05 '23	Sale	14.71	4,455	65,533	242,595	Sep 05 08:10 PM
ROTE WILLIAM E.	Senior Vice President, R&D	Sep 05 '23	Sale	14.71	1,815	26,699	61,173	Sep 05 08:13 PM
REED ELIZABETH E	SVP, GC & Corporate Secretary	Sep 05 '23	Sale	14.71	1,815	26,699	58,096	Sep 05 08:12 PM
Cline Christopher R.	Chief Financial Officer	Sep 05 '23	Sale	14.71	457	6,723	50,574	Sep 05 08:15 PM
Calvin Sandra	SVP, Chief Accounting Officer	May 11 '23	Sale	16.12	122	1,967	42,247	May 12 04:06 PM
REED ELIZABETH E	SVP, GC & Corporate Secretary	May 10 '23	Sale	16.59	825	13,687	56,611	May 12 04:11 PM
ROTE WILLIAM E.	Senior Vice President, R&D	May 10 '23	Sale	16.59	825	13,687	59,211	May 12 04:09 PM
Cline Christopher R.	Chief Financial Officer	May 10 '23	Sale	16.59	455	7,548	51,031	May 12 04:14 PM
Calvin Sandra	SVP, Chief Accounting Officer	May 10 '23	Sale	16.59	436	7,233	42,369	May 12 04:06 PM

Open in Screener

FATE

Fate Therapeutics Inc

May 01 • 04:00PM ET

4.09

Dollar change +0.14
Percentage change 3.54	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

FATE Fate Therapeutics Inc daily Stock Chart

Held by: VTI VXF IWM IWN VTWO LABU DWAS VHT SCHA PTH

Index	RUT	P/E	-	EPS (ttm)	-1.63	Insider Own	12.59%	Shs Outstand	113.82M	Perf Week	-4.88%
Market Cap	465.52M	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-0.24%	Shs Float	99.49M	Perf Month	-39.85%
Income	-160.93M	PEG	-	EPS next Q	-0.48	Inst Own	92.72%	Short Float	19.02%	Perf Quarter	-33.60%
Sales	63.53M	P/S	7.33	EPS this Y	-17.52%	Inst Trans	-2.88%	Short Ratio	6.88	Perf Half Y	136.42%
Book/sh	3.74	P/B	1.09	EPS next Y	6.23%	ROA	-26.56%	Short Interest	18.92M	Perf Year	-35.69%
Cash/sh	2.77	P/C	1.48	EPS next 5Y	-	ROE	-37.76%	52W Range	1.63 - 8.83	Perf YTD	9.36%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-6.65%	ROI	-34.55%	52W High	-53.68%	Beta	1.80
Dividend TTM	-	Quick Ratio	8.48	Sales past 5Y	87.14%	Gross Margin	71.22%	52W Low	150.92%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	8.48	EPS Y/Y TTM	43.83%	Oper. Margin	-299.86%	RSI (14)	27.41	Volatility	8.61% 7.87%
Employees	181	Debt/Eq	0.28	Sales Y/Y TTM	-34.03%	Profit Margin	-253.30%	Recom	2.56	Target Price	7.64
Option/Short	Yes / Yes	LT Debt/Eq	0.26	EPS Q/Q	22.82%	Payout	-	Rel Volume	1.57	Prev Close	3.95
Sales Surprise	8.97%	EPS Surprise	13.83%	Sales Q/Q	-96.22%	Earnings	Feb 26 AMC	Avg Volume	2.75M	Price	4.09
SMA20	-24.09%	SMA50	-37.28%	SMA200	0.61%	Trades		Volume	4,328,337	Change	3.54%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-23	Resumed	Wells Fargo	Equal Weight	$6
Jan-24-23	Downgrade	H.C. Wainwright	Buy → Neutral	$115 → $7
Jan-06-23	Downgrade	Wedbush	Outperform → Neutral	$42 → $7
Jan-06-23	Downgrade	Truist	Buy → Hold	$46 → $7
Jan-06-23	Downgrade	Stifel	Buy → Hold	$107 → $5.30
Jan-06-23	Downgrade	Piper Sandler	Overweight → Neutral	$71 → $12
Jan-06-23	Downgrade	Cowen	Outperform → Market Perform
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$72 → $4
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$20 → $7
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Dec-15-22	Initiated	Goldman	Sell	$10
Nov-04-22	Resumed	Cantor Fitzgerald	Overweight	$98 → $45
Oct-10-22	Initiated	Canaccord Genuity	Buy	$42
Aug-18-22	Resumed	Wells Fargo	Overweight	$90
Jul-28-22	Initiated	Needham	Hold
Jul-11-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$50 → $47
Jun-03-22	Initiated	Robert W. Baird	Neutral	$28
Feb-11-22	Resumed	BMO Capital Markets	Market Perform	$50
Dec-15-21	Upgrade	Wedbush	Neutral → Outperform

Show Previous Ratings

Apr-22-24 04:30PM	Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting (GlobeNewswire)
Apr-06-24 02:17AM	Fate Therapeutics (FATE) Surges 86.4% YTD on Pipeline Progress (Zacks)
Apr-04-24 11:30PM	NOTICE TO LONG-TERM SHAREHOLDERS OF FATE THERAPEUTICS, INC. (FATE): GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON YOUR BEHALF (Newsfile)
Apr-03-24 08:00AM	Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
11:30AM	Loading…
Mar-27-24 11:30AM	Fate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound? (Zacks) +7.00%
Mar-19-24 08:44AM	Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement (GlobeNewswire)
Mar-05-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 08:09AM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.17%
08:00AM	Fate Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Feb-27-24 09:16AM	Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y (Zacks) +7.34%
08:07AM	Q4 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-26-24 05:10PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:35PM	Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
04:08PM	Fate Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-19-24 10:00AM	Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-15-24 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.09%
Feb-02-24 04:01PM	Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-30-24 07:54AM	Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-29-24 02:53PM	Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock (InvestorPlace) +25.44%
Jan-08-24 08:00AM	Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors (GlobeNewswire) +9.28%
Dec-22-23 12:00PM	Fate Therapeutics (FATE) Upgraded to Buy: Here's Why (Zacks)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 05:00PM	Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +11.67%
Dec-08-23 11:30AM	Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 01:18PM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2023 Earnings Call Transcript (Insider Monkey) -8.58%
Nov-08-23 06:18PM	Fate Therapeutics Inc (FATE) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
04:08PM	Fate Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Oct-25-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results (GlobeNewswire) -7.22%
Sep-15-23 06:01AM	Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength? (Zacks) -6.78%
Sep-07-23 11:30AM	Why Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report? (Zacks)
Aug-31-23 08:00AM	Fate Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-29-23 07:30AM	16 Most Shorted Stocks Right Now (Insider Monkey)
Aug-09-23 12:12PM	FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss (Zacks)
11:04AM	Q2 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-08-23 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:11PM	Fate Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jul-28-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-22-23 08:35AM	One Fate Therapeutics Insider Raised Stake By 83% In Previous Year (Simply Wall St.)
Jul-01-23 10:33AM	We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-16-23 03:53PM	Why Shares of Fate Therapeutics Soared This Week (Motley Fool)
Jun-14-23 06:42AM	Editas (EDIT) Surges 15.5%: Is This an Indication of Further Gains? (Zacks)
Jun-08-23 11:30AM	Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-07-23 11:30AM	Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report? (Zacks)
Jun-04-23 08:27AM	Fate Therapeutics, Inc.'s (NASDAQ:FATE) Low P/S No Reason For Excitement (Simply Wall St.)
Jun-02-23 11:31AM	Fate Therapeutics (FATE) Down 17.8% Since Last Earnings Report: Can It Rebound? (Zacks)
May-31-23 08:00AM	Fate Therapeutics to Present at Upcoming June Investor Conferences (GlobeNewswire)
May-25-23 10:49AM	Cathie Wood is Selling These 12 Stocks in 2023 (Insider Monkey) -5.62%
May-08-23 06:05AM	Broker Revenue Forecasts For Fate Therapeutics, Inc. (NASDAQ:FATE) Are Surging Higher (Simply Wall St.)
May-04-23 11:59AM	FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses (Zacks)
11:22AM	Q1 2023 Fate Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-03-23 05:15PM	Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.76%
04:11PM	Fate Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Fate Therapeutics Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
12:00PM	Fate Therapeutics (FATE) Upgraded to Buy: Here's What You Should Know (Zacks)
Apr-27-23 10:03AM	Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-26-23 10:02AM	Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-24-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results (GlobeNewswire)
Apr-12-23 07:20AM	Shareholders in Fate Therapeutics (NASDAQ:FATE) are in the red if they invested a year ago (Simply Wall St.)
Mar-30-23 11:30AM	Why Is Fate Therapeutics (FATE) Down 8.9% Since Last Earnings Report? (Zacks)
Mar-27-23 09:00AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Mar-03-23 04:01PM	Fate Therapeutics to Present at Upcoming March Investor Conferences (GlobeNewswire)
Mar-02-23 09:18PM	Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Call Transcript (Insider Monkey)
05:30AM	Fate Therapeutics Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-01-23 09:59AM	FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Feb-28-23 05:15PM	Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Feb-27-23 09:31AM	Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More (Zacks)
Feb-13-23 08:00AM	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-06-23 09:55AM	Wall Street Analysts Believe Fate Therapeutics (FATE) Could Rally 172.49%: Here's is How to Trade (Zacks)
Feb-02-23 09:46AM	GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities (GlobeNewswire) +7.22%
Jan-30-23 07:33AM	Calculating The Fair Value Of Fate Therapeutics, Inc. (NASDAQ:FATE) (Simply Wall St.)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)
Jan-19-23 09:35AM	Down -52.57% in 4 Weeks, Here's Why Fate Therapeutics (FATE) Looks Ripe for a Turnaround (Zacks)
Jan-17-23 06:27AM	Daily Vickers Top Buyers & Sellers for 01/17/2023 (Argus Research) +5.93%
Jan-06-23 01:55PM	FATE To End Janssen Deal and Prioritize Pipeline Development (Zacks) -61.45%
10:54AM	Tesla Falls Again, but This Nasdaq Stock Is Truly Plunging (Motley Fool)
10:27AM	Fate Therapeutics Ends Collaboration Deal With Janssen, Cuts Staff (Benzinga)
08:49AM	Fate Therapeutics stocks heads for record selloff after Janssen collaboration terminated and job cuts (MarketWatch)
Jan-05-23 05:00PM	Fate Therapeutics Announces Termination of Collaboration Agreement with Janssen, Pipeline Prioritization, Next-Generation Programs, and Key 2023 Initiatives (GlobeNewswire)
07:40AM	Strength Seen in Fate Therapeutics (FATE): Can Its 9.3% Jump Turn into More Strength? (Zacks)
Jan-03-23 09:35AM	Fate Therapeutics (FATE) Loses -50.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-02-23 08:39AM	Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely? (Simply Wall St.)
Dec-13-22 08:00AM	Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting (GlobeNewswire)
Dec-12-22 07:30AM	GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022 (GlobeNewswire) -14.29%
Dec-10-22 02:46PM	Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting (GlobeNewswire)
10:00AM	Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting (GlobeNewswire)
Nov-09-22 03:55PM	9 Cheap Stocks to Buy According to Cathie Wood (Insider Monkey)
Nov-07-22 08:00AM	Fate Therapeutics Announces Exercise by ONO Pharmaceutical of Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors (GlobeNewswire)
Nov-04-22 04:01PM	Fate Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-03-22 05:35PM	Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Fate Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Operational Progress (GlobeNewswire)
09:00AM	Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting (GlobeNewswire)
Nov-01-22 10:01AM	Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-31-22 08:49AM	Top 10 Stock Picks of Eli Casdins Casdin Capital (Insider Monkey)
Oct-27-22 10:03AM	Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for (Zacks)

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dulac Edward J III	Chief Financial Officer	Mar 04 '24	Sale	7.77	2,447	19,013	101,479	Mar 05 04:24 PM
Dulac Edward J III	Chief Financial Officer	Jan 29 '24	Sale	5.00	1,849	9,245	103,926	Jan 30 04:01 PM
Wolchko J Scott	President and CEO	Jan 09 '24	Sale	4.37	14,391	62,889	371,248	Jan 10 04:29 PM
Valamehr Bahram	Chief R&D Officer	Jan 09 '24	Sale	4.38	11,271	49,367	158,069	Jan 10 04:30 PM
TAHL CINDY	General Counsel and Secretary	Jan 09 '24	Sale	4.37	10,874	47,519	142,361	Jan 10 04:30 PM
Dulac Edward J III	Chief Financial Officer	Jan 09 '24	Sale	4.37	7,028	30,712	105,775	Jan 10 04:29 PM
Dulac Edward J III	Chief Financial Officer	Jan 02 '24	Sale	3.66	5,182	18,966	112,803	Jan 03 04:03 PM
Redmile Group, LLC	Director	Dec 26 '23	Buy	3.72	44,630	166,024	13,180,388	Dec 28 09:30 PM
Dulac Edward J III	Chief Financial Officer	Dec 18 '23	Sale	3.50	1,585	5,548	117,985	Dec 19 04:01 PM
TAHL CINDY	General Counsel and Secretary	Nov 09 '23	Sale	2.40	24,363	58,471	153,235	Nov 13 04:01 PM
Dulac Edward J III	Chief Financial Officer	Aug 18 '23	Sale	2.80	4,718	13,210	119,570	Aug 21 04:02 PM
Xu Yuan	Director	Aug 04 '23	Sale	3.71	632	2,345	9,302	Aug 07 04:01 PM
Dulac Edward J III	Chief Financial Officer	Jul 05 '23	Sale	4.83	5,182	25,029	124,288	Jul 06 05:18 PM
Powl Brian T.	Chief Commercial Officer	Jul 05 '23	Sale	4.87	3,854	18,769	41,146	Jul 06 05:19 PM
Xu Yuan	Director	Jun 14 '23	Sale	5.58	3,460	19,307	9,934	Jun 15 04:05 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

LIFE

Atyr Pharma Inc

TVTX

Travere Therapeutics Inc

FATE

Fate Therapeutics Inc

Upgrade your FINVIZ experience